The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Pharmacokinetics of Novel Erythropoiesis Stimulating Protein Compared with Epoetin Alfa in Dialysis Patients
Abstract
Novel erythropoiesis stimulating protein (NESP) is a hyperglycosylated analogue of recombinant human erythropoietin (Epoetin) which has an increased terminal half-life in animal models. The aim of this study was to extend these observations to humans. Using a double-blind, randomized, cross-over design, the single-dose pharmacokinetics of Epoetin alfa (100 U/kg) and an equivalent peptide mass of NESP were compared following intravenous bolus in 11 stable peritoneal dialysis patients. This was followed by an open-label study to determine the single-dose pharmacokinetics of an equivalent peptide mass of NESP by subcutaneous injection in six of these patients. The mean terminal half-life for intravenous NESP was threefold longer than for intravenous Epoetin (25.3 versus 8.5 h), a difference of 16.8 h (95% confidence interval, 9.4 to 24.2 h, P = 0.0008). The area under the serum concentration-time curve was significantly greater for NESP (291.0 +/- 7.6 ng x h per ml versus 131.9 +/- 8.3 ng x h per ml; mean +/- SEM; P < 0.0005), and clearance was significantly lower (1.6 +/- 0.3 ml/h per kg versus 4.0 +/- 0.3 ml/h per kg; mean +/- SEM; P < 0.0005). The volume of distribution was similar for NESP and Epoetin (52.4 +/- 2.0 ml/kg versus 48.7 +/-2.1 ml/kg; mean +/-SEM). The mean terminal half-life for subcutaneous NESP was 48.8 h. The peak concentration of subcutaneous NESP was approximately 10% of that following intravenous administration, and bioavailability was approximately 37% by the subcutaneous route. The longer half-life of NESP is likely to confer a clinical advantage over Epoetin by allowing less frequent dosing in patients treated for anemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biological roles of oligosaccharides: all of the theories are correct
Varki, A. (1993) · Glycobiology · doi:10.1093/glycob/3.2.97 · Cited by 5,195
Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin
Eschbach, J. W., Egrie, J. C., Downing, M. R., Browne, J. K., & Adamson, J. W. (1987) · New England Journal of Medicine · doi:10.1056/nejm198701083160203 · Cited by 2,005
Self-citationWinearls, C., Pippard, M., Downing, M., Oliver, D., Reid, C., & Mary Cotes, P. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92192-6 · Cited by 1,401
The two‐period cross‐over clinical trial.
Hills, M., & Armitage, P. (1979) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1979.tb05903.x · Cited by 1,395
Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta
Halstenson, C. E., Macres, M., Katz, S. A., Schnieders, J. R., Watanabe, M., Sobota, J. T., & Abraham, P. A. (1991) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1991.210 · Cited by 198
Macdougall, I. C., Neubert, P., Coles, G., Roberts, D. E., Dharmasena, A. D., & Williams, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90014-7 · Cited by 150
Self-citationClinical Pharmacokinetics of Epoetin (Recombinant Human Erythropoietin)
Macdougall, I. C., Roberts, D. E., Coles, G. A., & Williams, J. D. (1991) · Clinical Pharmacokinetics · doi:10.2165/00003088-199120020-00002 · Cited by 127
Self-citationFaulds, D. M., & Sorkin, E. M. (1989) · Drugs · doi:10.2165/00003495-198938060-00004 · Cited by 84
S7.7 The role of carbohydrate on the biological activity of erythropoietin
Egrie, J. C., Grant, J. R., Gillies, D. K., Aoki, K. H., & Strickland, T. W. (1993) · Glycoconjugate Journal · doi:10.1007/bf01209934 · Cited by 75
Self-citationClinical Pharmacology of Recombinant Human Erythropoietin (r‐HuEPO)
Flaharty, K. K. (1990) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1990.tb02567.x · Cited by 26
Cited by
Erythropoietin: Physiology and Pharmacology Update
Fisher, J. W. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800101 · Cited by 708
Enhancement of therapeutic protein in vivo activities through glycoengineering
Elliott, S., Lorenzini, T., Asher, S., Aoki, K., Brankow, D., Buck, L., Busse, L., Chang, D., Fuller, J., Grant, J., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt799 · Cited by 510
Self-citationDevelopment and characterization of novel erythropoiesis stimulating protein (NESP)
Egrie, J. C., & Browne, J. K. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1746 · Cited by 510
Self-citationVansteenkiste, J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.16.1211 · Cited by 477
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
Strohl, W. R. (2015) · BioDrugs · doi:10.1007/s40259-015-0133-6 · Cited by 461
Metadata
- Authors
- MACDOUGALL, I. C., GRAY, S. J., ELSTON, O., BREEN, C., JENKINS, B., BROWNE, J., & EGRIE, J.
- Venue
- Journal of the American Society of Nephrology
- Published
- 1999-11
- Volume
- 10
- Issue
- 11
- Pages
- 2392-2395
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2108511043
- Cited by
- 433
- References
- 10
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics of Novel Erythropoiesis Stimulating Protein Compared with Epoetin Alfa in Dialysis Patients. https://app.cochat.ai/papers/10.1681/asn.v10112392
- The paper
- MACDOUGALL, I. C., GRAY, S. J., ELSTON, O., BREEN, C., JENKINS, B., BROWNE, J., & EGRIE, J. (1999). Pharmacokinetics of Novel Erythropoiesis Stimulating Protein Compared with Epoetin Alfa in Dialysis Patients. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.v10112392
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.